Biotech Networking Event with VectivBio: From Inception to IPO in Two Years (EN)

Date

08.12.21

Time

16:00 - 18:00

Location

Online
Share event
Martyna Wroblewska

Organizer

Martyna Wroblewska
Phone
+41 79 645 67 18
Email
martyna.wroblewska@baselaunch.ch
Baselaunch KPMG VectivBio event

BaseLaunch and KPMG invite you participate in this online event, powered by Innosuisse, featuring VectivBio.

KPMG is a leading professional services firm in Switzerland. Through its strong regional presence KPMG is close to you, helping you navigate today’s turbulences to find tomorrow’s answers. In audit, tax and advisory, KPMG is noted for clear and consistent solutions. KPMGs life sciences experts have a deep understanding of the industry to support companies in challenges around cost & efficiency, valuation & financing or regulatory compliance.

VectivBio (Nasdaq: VECT) is a global, clinical-stage biotechnology company focused on the discovery, development and commercialization of innovative treatments for severe rare conditions with high unmet medical need. Formed in 2019 as a spin-off from Therachon, a biotech company acquired by Pfizer, the Company went public in April of this year – less than two years after inception!

VectivBio is headquartered in Basel, Switzerland, and maintains a presence in the U.S. where it is listed on the Nasdaq exchange. Its product candidate, apraglutide, is a next-generation, long-acting synthetic GLP-2 analog being developed for a range of rare gastrointestinal diseases where GLP-2 can play a central role in addressing disease pathophysiology, including short bowel syndrome with intestinal failure (SBS-IF) and Acute Graft-Versus-Host Disease (aGVHD). Following VectivBio’s successful acquisition of Comet Therapeutics in September, VectivBio’s pipeline has since expanded to include the CoMET Platform, a modular small molecule platform designed to address severe Inherited Metabolic Diseases (IMDs) in pediatric populations.

Join us in hearing from Luca Santarelli, M.D., Ph.D., Founder and CEO of VectivBio, who will speak about the Company’s journey to IPO and share his thoughts on key strategic business development considerations necessary to build a fully integrated global biopharmaceutical company.

Program

16:00

Welcome
Martyna Wroblewska BaseLaunch

16:05

Introduction by KPMG
Martin Rohrbach, Head of Life Sciences & Chemicals KPMG
Peter Mozerov, Manager Life Science Strategy KPMG

16:20

VectiveBio
Luca Santarelli M.D., Ph.D., Founder and CEO

16:45

Q&A

17:15

1:1 Networking

Participation is free, however, registration is required before December 7, 2021.

Co-organized with

Presenting Partner